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We present novel data demonstrating that the expression of PPARγ is reduced in lung ﬁbroblasts from black SSc-ILD patients as
compared to white patients. Activating PPARγ with the agonist rosiglitazone increased the expression of MMP-1 and inhibited
collagen type I in lung ﬁbroblasts isolated from white, but not black, SSc-ILD patients. Blocking the c-Met receptor abolishes
rosiglitazone’s eﬀects on collagen and MMP-1 in lung ﬁbroblasts isolated from white SSc-ILD patients, while augmenting the
expression of the c-Met receptor in ﬁbroblasts from black SSc-ILD patients replicates the eﬀects of rosiglitazone seen in whites.
We conclude that PPARγ agonists warrant consideration as potential antiﬁbrotic drugs in patients with SSc-ILD. Diﬀerential
therapeutic eﬀects might be anticipated especially relative to racial diﬀerences and the functional expression of the c-Met receptor.
1.Introduction
PPARγ is a ligand-dependent transcription factor belong-
ing to the nuclear steroid/retinoid/vitamin D receptor
superfamily that plays a pivotal role in the regulation of
adipogenesis, insulin sensitivity, glucose homeostasis, and
immune response (reviewed in [1, 2]). Activation of PPARγ
inhibits the proinﬂammatory eﬀects of lipopolysaccharide
and various cytokines on immune cells. PPARγ is detectable
in normal lung where it is expressed in epithelial cells,
smooth muscle cells, and alveolar macrophages [3–5].
Reduced PPARγ nuclear protein and gene expression has
been demonstrated in dermal ﬁbroblasts and in lung and
skin biopsies from patients with SSc [6, 7], and in alveolar
macrophages of patients with sarcoidosis and pulmonary
alveolarproteinosis[4,8],suggestingthatinsuﬃcientPPARγ
activity may contribute to ongoing dysregulated inﬂamma-
tion and ﬁbrosis.
In normal skin ﬁbroblasts, ligand activation of cellular
PPARγ has been shown to reduce basal collagen gene
expression and abrogate TGF-β-induced stimulation [9].
PPARγ ligandsalsoabrogateTGF-β-inducedexpressionofα-
SMA, a marker of myoﬁbroblasts, and suppress stimulation
of Smad-dependent transcriptional responses to TGF-β [9].
Recently, Kapoor et al. demonstrated that a loss of PPARγ
in mouse ﬁbroblasts results in increased susceptibility to
bleomycin-induced skin ﬁbrosis [10]. Activating PPARγ
with rosiglitazone was shown to alleviate the persistent
ﬁbrotic phenotype of lesional skin scleroderma ﬁbroblasts
[6] and to attenuate inﬂammation, dermal ﬁbrosis, and
subcutaneous lipoatrophy in a murine model of scleroderma
[11], suggesting that PPARγ ligands may be considered as
potential therapeutic agents for scleroderma.
Similar eﬀects have been reported from studies of
lung ﬁbroblasts [12]. Burgess et al. have shown that both
endogenous and synthetic PPARγ agonists (15d-PGJ2 and
ciglitazone or rosiglitazone, resp.) are able to block key TGF-
β-mediated proﬁbrotic eﬀects in vitro, including pulmonary
myoﬁbroblast diﬀerentiation and excess collagen produc-
tion, without aﬀecting cell viability. 15d-PGJ2 inhibited
>95% of the TGF-β-stimulated α-SMA induction, whereas
rosiglitazone inhibited 40% of the TGF-β-stimulated α-SMA2 Pulmonary Medicine
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Figure 1: PPARγ expression in lung ﬁbroblasts. (a) Western blot for PPARγ on lung ﬁbroblasts isolated from white (W) and black (B)
SSc-ILD patients and controls. Anti-β-actin antibody was used as a loading control. (b) Densitometric analysis of PPARγ in lung ﬁbroblasts
(n = 16)from3independentexperimentsispresented.PPARγ proteinexpressionwasadjustedinaccordancewithβ-actinlevel. ∗Statistically
signiﬁcant diﬀerences.
[12]. Such ﬁndings may be particularly relevant to SSc-ILD,
since we and others have demonstrated elevated levels of
TGF-β [13, 14], as well as the presence of myoﬁbroblasts
expressingincreasedlevelsofα-SMA[15]inbronchoalveolar
lavage ﬂuid (BALF). The present study demonstrates in vitro
antiﬁbrotic eﬀects of the PPARγ agonist rosiglitazone in lung
ﬁbroblasts derived from patients with SSc-ILD, providing
additional support for a potential new role for PPARγ
agonists as antiﬁbrotic therapy in patients with SSc-ILD.
2.MaterialsandMethods
2.1. Materials. Rosiglitazone and GW 9662 were pur-
chased from Cayman Chemical, Ann Arbor, Mich, USA;
EnzoLytePlus 520 MMP-1 Assay Kit was obtained from
AnaSpec(SanJose,Calif,USA);NoShiftTranscriptionFactor
Assay Kit, NoShift NF-κB (p65) reagents, and NucBuster
Protein Extraction Kit were purchased from Novagen (Madi-
son, Wis); MMP inhibitor GM1489 was obtained from EMD
Biosciences (San Diego, Calif). Anti-PPARγ polyclonal anti-
body was purchased from Cell Signaling Technology (Dan-
vers, Mass); anti-α-SMA and anti-β-actin antibodies were
purchased from Sigma-Aldrich (St. Louis, Mo); antitype
I collagen antibody was purchased from SouthernBiotech
(Birmingham, Alaska). Anti-CTGF antibody and anti-Met
(C-12) antibody were obtained from Santa Cruz Biotech-
nology (Santa Cruz, Calif). c-Met-pLXSN cDNA was kindly
provided by Dr. Morag Park (McGill University, Montreal,
Canada). Rosiglitazone was prepared as 20mM, GW 9662
as 2mM, and GM1489 as 1mM stocks in DMSO, and the
same amounts of DMSO as in rosiglitazone-, GW 9662-, and
GM1489-treated cells were added to control cell cultures.
2.2. Cell Culture and Transfection. Lung ﬁbroblasts were
derived from lung tissue obtained at autopsy from 5 White
and 5 African American patients with end-stage SSc lung
disease (1 male, 4 females per each group) and from normal
subjects (1 male, 2 females per each group) as described
previously [16]. Lung ﬁbroblasts were used between the
second and fourth passages in all experiments. The mean ±
SD age of the SSc patients was 57.8 ± 10.2 years in the
white group and 42.2 ± 9.7 in the African American group.
The mean ± S Da g eo fn o r m a ls u b j e c t sw a s5 3 . 3± 4.7
years in the whites and 46.3 ± 5.6 in the African American
group. The diﬀerence in age between whites and African
Americanswasnotstatisticallysigniﬁcanteitherincontrolor
insclerodermapatients(P>0.05).Inonesetofexperiments,
cells were transfected with c-Met-pLXSN cDNA by Eﬀectene
reagent (Qiagen, Valencia, Calif) according to manufac-
turer’s instructions as described previously [17].
2.3. Enzyme-Linked Immunosorbent Assay (ELISA) for Hepa-
tocyte Growth Factor (HGF). Levels of HGF were measured
in 50μL samples of cell culture medium using Quantikine
human HGF ELISA kit (R & D Systems, Minneapolis,
Minn) according to manufacturer’s instructions as described
previously [16].
2.4. EnzoLytePlus Assay. MMP-1 activity was measured in
samples consisting of 100μL of cell culture medium by
EnzoLytePlus 520 Assay according to the manufacturer’s
instructions as described previously [18].
2.5. NF-κB DNA-Binding Activity Assay. Nuclear protein
extracts were prepared from lung ﬁbroblasts incubated with
and without rosiglitazone (20μM) for 24 hours using Nuc-
Buster Protein Extraction Kit from Novagen in accordance
with manufacturer’s instructions. Protein concentration was
determined using BCA protein assay kit (Pierce, Rockford,
Ill). Nuclear extracts (25μg each) from lung ﬁbroblasts or
from HeLa-positive control cells provided by manufacturer
were incubated with various combinations of biotinylated
NF-κB wild-type dsDNA, speciﬁc NF-κB competitor dsDNA
lacking biotin end labels, and nonspeciﬁc, nonbiotinylated
dsDNA with a mutant NF-κB consensus binding motif.
DNA-binding activity of NF-κB was determined using the
NoShift Transcription Factor Assay Kit and NoShift NF-κB
(p65) reagents as described previously [18].
2.6. Preparation of Cell Extracts and Immunoblotting. Lung
ﬁbroblasts were cultured to conﬂuence on 100mm dishes,Pulmonary Medicine 3
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Figure 2: Eﬀect of rosiglitazone on MMP-1 and collagen I in lung ﬁbroblasts. (a) MMP-1 activity in lung ﬁbroblasts. Each bar represents the
mean and SD of duplicate determinations in 4 independent experiments. (b) Eﬀect of rosiglitazone on collagen type I in white normal (1),
whitescleroderma(2),blacknormal(3),andblackscleroderma(4)lungﬁbroblasts.(c)PPARγ antagonistGWinhibitseﬀectofrosiglitazone
on collagen in white scleroderma ﬁbroblasts. Immunoblots in (b) and (c) are representative of 5 independent experiments. The results of
immunoblot analysis were quantiﬁed. Values are the mean and SD of densitometry units corresponding to the α1a n dα2 chains of type I
collagen. ∗P<0.05 versus unstimulated cells.
maintained in serum-free DMEM overnight, and then
treated with or without rosiglitazone. In some experiments,
cells were pretreated with neutralizing anti-c-Met antibody
(R&DSystems,Minneapolis,Minn),PPARγ antagonistGW
9662 or MMP inhibitor GM1489. Normal goat IgG served
as a negative control with c-Met neutralizing antibody. Lung
ﬁbroblastswerewashed withice-coldPBSand lysedwith ice-
cold lysis buﬀer (10mM Tris, 10mM EDTA, 1% Nonidet
P-40, 0.5% deoxycholate, 0.1% SDS, pH = 7.4). Protein
concentration was determined by BCA protein assay in
accordance with manufacturer’s instructions (Pierce, Rock-
ford, Ill). For each sample, 40μgo fp r o t e i nw a sd e n a t u r e d ,
subjected to SDS-polyacrylamide gel electrophoresis, and
analyzed by immunoblotting with appropriate antibodies.
The immunoblots were then stripped and reblotted with
anti-β-actin antibody as a loading control. Western blotting
for CTGF was performed as described previously [19].
2.7.c-MetReceptorPhosphorylation. Sclerodermalungﬁbro-
blasts were cultured to conﬂuence on six-well plates, main-
tained in serum-free DMEM overnight, and then treated
with or without rosiglitazone for various times. The cells
were transferred on ice, washed with ice-cold PBS, collected
with 1 × SDS sample buﬀer (100μL/well) for denaturing
gelelectrophoresis(4–20%SDS-PAGE),andimmunoblotted4 Pulmonary Medicine
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Figure 3: Rosiglitazone increases PPARγ expression in SSc lung
ﬁbroblasts in a time-dependant manner. Lung ﬁbroblasts were
incubated with rosiglitazone (20μM) for time indicated. Cells were
collected and subjected to Western analysis for PPARγ expression.
Anti-β-actin antibody was used as a loading control. Immunoblots
are representative from 3 independent experiments.
with anti-phospho-c-Met [pYpYpY1230/1234/1235] polyclonal
antibody (BioSource International, Inc., Camarillo, Calif).
In each experiment, the membrane transfers used for
immunoblotting were evaluated for total amount of c-
Met receptor by reblotting with anti-Met (C-12) polyclonal
antibody (Santa Cruz Biotechnology).
2.8. Statistical Analysis. Statistical analyses were performed
with KaleidaGraph 4.0 (Synergy Software, Reading, Pa). All
data were analyzed using nonparametric Wilcoxon-Mann-
Whitney tests and ANOVA with Tukey HSD post hoc testing.
The results were considered signiﬁcant if P<0.05.
3. Results
3.1. PPARγ Expression in Lung Fibroblasts. To better under-
stand the role of PPARγ in the pathogenesis of SSc lung
disease, we investigated the expression of PPARγ in lung
ﬁbroblasts isolated from SSc-ILD patients and controls.
We measured PPARγ expression by Western blotting in 6
controls (3 white and 3 black) and 10 SSc ﬁbroblast cell
lines isolated from patients with end-stage SSc-ILD (5 white
and 5 black). PPARγ levels were signiﬁcantly reduced in SSc
lung ﬁbroblasts (43.5 ± 18.3 versus 101.1 ± 7.9, P<0.001)
(Figure 1). We next compared PPARγ expression between
ﬁbroblasts derived from white and black normal controls
and SSc patients. We found that lung ﬁbroblasts from white
SSc-ILDpatientshadsigniﬁcantlygreaterPPAR-γ expression
compared to black SSc-ILD ﬁbroblasts (57.4 ± 11.8 versus
29.6 ± 11.3, P<0.05).
3.2.DiﬀerentialEﬀectsofPPARγ inFibroblastsfromWhiteand
Black SSc-ILD Patients. We sought to compare the eﬀects
of rosiglitazone in diﬀerent lines of lung ﬁbroblasts. We
tested 10 SSc-ILD cell lines (5 from black and 5 from white
patients) and 6 normal lung ﬁbroblasts (3 from black and
3 from white). When lung ﬁbroblasts were treated with
rosiglitazone in a concentration of 20μM for 24 hours,
MMP-1 activity was increased in lung ﬁbroblasts from white
SSc-ILD patients; such treatment, however, had no eﬀect on
MMP-1 activity in SSc-ILD ﬁbroblasts from black patients
(Figure 2(a)). Rosiglitazone notably reduced collagen after
48 hours of treatment in lung ﬁbroblasts from white but
not black SSc-ILD patients (Figure 2(b)). The eﬀects of
rosiglitazone on MMP-1 and collagen were inhibited by the
PRARγ antagonist,GW9662,indicatingaPPARγ-dependent
mechanism (Figures 2(a) and 2(c)). Rosiglitazone had no
eﬀects on MMP-1 and collagen in either white or black
normal lung ﬁbroblasts.
3.3. Eﬀect of Rosiglitazone on PPARγ Expression, CTGF, α-
SMA, and NF-κB DNA Binding Activity in Lung Fibroblasts.
To investigate whether rosiglitazone would increase the
level of PPARγ in lung ﬁbroblasts, we incubated cells with
rosiglitazone for diﬀerent times and then analyzed PPARγ
expression by immunoblotting. We observed that exposure
of ﬁbroblasts to rosiglitazone for ≥12 hours results in
signiﬁcantly increased levels of PPARγ in both white and
black SSc lung ﬁbroblasts. However, rosiglitazone had no
eﬀects on PPARγ expression in normal lung ﬁbroblasts
(Figure 3).
Rosiglitazone has been reported to suppress CTGF and
α-SMA protein expression in lesional SSc skin ﬁbroblasts
[6]. To determine whether rosiglitazone inhibits expression
of CTGF and α-SMA in various SSc lung ﬁbroblasts, we
investigated protein expression of CTGF and α-SMA with
and without rosiglitazone in all tested cell lines. We found
that rosiglitazone reduces CTGF and α-SMA expression in
all SSc cell lines within 24 hours of treatment. No diﬀerence
between white and black lung ﬁbroblasts was observed. Also,
rosiglitazone had no eﬀects on CTGF and α-SMA in normal
lung ﬁbroblasts (Figure 4(a)).
Since PPARγ agonists are known to inhibit NF-κB
[20], we examined the eﬀect of rosiglitazone on NF-κB
activation in lung ﬁbroblasts. NF-κB DNA-binding activity
was assayed by the binding of NF-κB to oligonucleotides
containing the consensus binding site. Nuclear extracts from
HeLa cells stimulated with TNF-α were used as a positive
control. To assess sequence-speciﬁc binding activity, nuclear
extracts were incubated with NF-κB wild-type DNA, with or
without either a speciﬁc NF-κB competitor DNA or non-
speciﬁc mutant NF-κB consensus-binding motif. Nuclear
extracts incubated with NF-κB wild-type DNA expressed
actual NF-κBa c t i v i t y .T h es p e c i ﬁ cN F - κBc o m p e t i t o rD N A
reduced the binding activity in all cell lines conﬁrming
sequence speciﬁcity of the assay for NF-κB binding, but
binding activity of a nonspeciﬁc mutant did not signiﬁcantly
diﬀer among various conditions used in this experiment
(Figure 4(b)). Consistent with our previous observations
[18] ,b a s a ll e v e l so fa c t i v eN F - κB in SSc-ILD ﬁbroblasts were
higher than in TNF-α-induced HeLa cells used as a positive
control. Nuclear extracts prepared from either white or black
SSc-ILD ﬁbroblasts treated with rosiglitazone demonstrated
signiﬁcant reduction of NF-κB DNA binding (Figure 4(b)).
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Figure 4: Eﬀect of rosiglitazone on CTGF, α-SMA, and NF-κB in lung ﬁbroblasts isolated from white (W) and black (B) SSc-ILD patients
(SSc) and controls (N). (a) Lung ﬁbroblasts were incubated with rosiglitazone (20μM) for 24 hours and subjected to Western analysis for
CTGF and α-SMA expression. Anti-β-actin antibody was used as a loading control. Immunoblots are representative from 5 independent
experiments. (b) NF-κB DNA-binding activity. Light gray bars: binding activity assessed by biotinylated NF-κB wild-type (WT) double-
stranded DNA (dsDNA); dark gray bars: WT dsDNA plus nonspeciﬁc, nonbiotinylated dsDNA with a mutant NF-κB consensus-binding
motif; black bars: WT dsDNA plus speciﬁc NF-κB competitor dsDNA lacking biotin end labels; Neg: negative control. Each bar represents
the mean ± SD of duplicate determinations from 4 independent experiments. ∗Statistically signiﬁcant diﬀerences between nuclear extract
prepared from cells stimulated with rosiglitazone versus nuclear extracts from nonstimulated cells (P<0.05).
was notably reduced as compared with binding activity of
SSc lung ﬁbroblasts and was not aﬀected by rosiglitazone
(Figure 4(b)).
3.4. The Eﬀects of Rosiglitazone on HGF and c-Met in
LungFibroblastsIsolatedfromSSc-ILDPatients. SincePPARγ
binds to the peroxisome proliferator response element in
the HGF promoter region and induces HGF expression
in renal mesangial cells [21], we tested the eﬀects of
rosiglitazone on HGF expression in lung ﬁbroblasts. We
found that rosiglitazone induced the secretion of HGF
protein in cell supernatant to a similar extent in lung
ﬁbroblasts from both white and black subjects (Figure 5(a)).
Next, we tested whether HGF induced by PPARγ ago-
nist was suﬃcient to phosphorylate the c-Met receptor
in lung ﬁbroblasts. We measured the level of total and
phosphorylated c-Met receptor using anti-Met or anti-
phospho-c-Met [pYpYpY1230/1234/1235] polyclonal antibodies
and found that rosiglitazone had no eﬀect on the total
amount of c-Met receptor protein, yet it induced c-Met
receptor phosphorylation in SSc-ILD lung ﬁbroblasts from
white patients (Figure 5(b)). We previously demonstrated
thatlungﬁbroblastsfromblackSScpatientsareunresponsive
to HGF signaling and c-Met receptor phosphorylation [16].
In agreement with those data, we observed that rosiglitazone
did not aﬀect c-Met receptor phosphorylation in lung
ﬁbroblasts from black SSc-ILD patients (Figure 5(b)).
3.5. HGF Receptor c-Met Mediates the Eﬀects of Rosiglitazone
on Collagen in Lung Fibroblasts Isolated from White SSc-
ILD Patients. To investigate whether rosiglitazone-induced
inhibition of MMP-1 and collagen type I is mediated via a
c-Metreceptor-dependentmechanism,weemployedananti-
human HGF R (c-Met) antibody. This antibody was selected
for its ability to neutralize the receptor-ligand interaction.
We observed that the pretreatment of lung ﬁbroblasts
with neutralizing anti-c-Met antibody (2μg/mL) prevents
rosiglitazone-induced MMP-1 activity and reduces rosiglita-
zone’s inhibitory eﬀect on collagen expression (Figures 5(c)
and 5(d)). We also found that the MMP inhibitor, GM1489,
decreases the inhibitory eﬀect of rosiglitazone on collagen
(Figure 5(d)).
Overexpression of c-Met in lung ﬁbroblasts isolated
from white SSc-ILD patients resulted in increased basal and
rosiglitazone-induced activity of MMP-1; however, the dif-
ference between vector- and c-Met-transfected cells was not
signiﬁcant (Figure 6(a)). In contrast, we observed signiﬁcant
changes between lung ﬁbroblasts transfected with vector and
c-Met in cells isolated from black SSc-ILD patients. More-
over, rosiglitazone signiﬁcantly increased MMP-1 activity in
lungﬁbroblastsderivedfromblackpatientsaftertransfection
with c-Met receptor (Figure 6(a)). Overexpression of c-
Met in lung ﬁbroblasts isolated from either white or black
scleroderma patients results in reduced accumulation of
collagen. Treatment of such cells with rosiglitazone further
decreased the amount of collagen in these cells (Figure 6(b)).
4. Discussion
Interstitial lung disease (ILD) is an irreversible and pro-
gressive disease process and the major cause of death
among scleroderma patients (SSc-ILD). Characterized by
microvascular injury and inﬂammation, SSc-ILD culminates
in excessive deposition of extracellular matrix proteins, often
resulting in severe lung dysfunction and death [22, 23].
African-American (black) SSc patients have a higher risk of
developing SSc-ILD and tend to develop lung ﬁbrosis earlier
in the course of their disease and have a higher mortality
rate than white SSc patients [24]. Black SSc patients also6 Pulmonary Medicine
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Figure 5: Eﬀects of rosiglitazone in lung ﬁbroblasts are mediated in part by HGF. (a) Rosiglitazone induces HGF expression in SSc lung
ﬁbroblasts. Each bar represents the mean ± SD of duplicate determinations in four independent experiments. (b) Eﬀect of rosiglitazone
on c-Met receptor phosphorylation in lung ﬁbroblasts from white (cell lines 1 and 2) and black (cell lines 3 and 4) patients with SSc-ILD.
(c) Anti-c-Met antibody modulates MMP-1 activity in white SSc lung ﬁbroblasts. (d) Downregulation of collagen type I by rosiglitazone in
white SSc lung ﬁbroblasts depends on c-Met and MMP-1. Quantitative results of densitometric analysis of immunoblots presented in (b)
and (d) are shown; values are the mean and SD from 4 independent experiments. ∗P<0.05 versus unstimulated cells.
have a higher prevalence of the severe diﬀu s et y p eo fS S ca n d
a higher rate of the anti-Scl-70 autoantibody (antitopoiso-
merase I), which appears to be associated with an increased
risk for SSc lung disease with severe pulmonary ﬁbrosis
[25–27]. Despite these well-known associations, a potential
pathophysiologic link between black race and pulmonary
ﬁbrosis in SSc has not yet been identiﬁed. We previously
reportedthatcomparedtowhiteSSc-ILDpatients,blackSSc-
ILD patients are deﬁcient in c-Met receptor expression and
generatelessofthemultifunctionalandantiﬁbroticcytokine,
hepatocyte growth factor (HGF) [16]. Since HGF expression
is induced by PPARγ, the present study was undertaken to
investigate potential antiﬁbrotic eﬀects of a PPARγ agonist
in lung ﬁbroblasts isolated from SSc-ILD patients, including
both black and white subjects.
The mechanism by which PPARγ exerts its antiﬁbrotic
eﬀects is not yet fully understood. It was reported that
PPARγ agonists inhibit TGF-β-mediated diﬀerentiation of
ﬁbroblasts to a myoﬁbroblast phenotype, possibly via inhi-
bition of Smad3 phosphorylation and nuclear translocation
[28–31]. PPAR-γ ligands also block PDGF-dependent pro-
liferation and prolyl4-hydroxylase mRNA [32] and induce
tumor-suppressor phosphatase, tensin homologue deleted
on chromosome 10 (PTEN), which in vitro has been
shown to inhibit α-SMA and collagen in lung ﬁbroblasts
[33]. Recently, Li et al. demonstrated that PPARγ binds to
the peroxisome proliferator response element in the HGF
promoter region of renal mesangial cells, thereby inducing
HGF mRNA expression and protein secretion [21]. In the
present study, we demonstrate that in vitro treatment with
the PPARγ agonist rosiglitazone results in increased HGF
protein occurring in association with phosphorylation of the
c-Met receptor tyrosine kinase in lung ﬁbroblasts isolated
from white, but not black, SSc-ILD patients.Pulmonary Medicine 7
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Figure 6: Overexpression of c-Met receptor in lung ﬁbroblasts restores eﬀects of rosiglitazone on MMP-1 (a) and collagen type I (b) in
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loading control.
The diﬀerences between Caucasian and African-
American lung ﬁbroblasts were observed in cells derived
from SSc patients but not in controls. This would suggest
thatotherethnic-speciﬁcfactorsrelatedtosclerodermacome
into play in SSc-ILD. Recently, Hoshino et al. demonstrated
an association of HGF promoter polymorphism with
severity of ILD in Japanese patients with systemic sclerosis
[34]. We previously showed that HGF’s antiﬁbrotic eﬀect is
signiﬁcantly reduced in lung ﬁbroblasts isolated from black
subjects [16]. Our results were consistent across diﬀerent
cell lines of SSc-ILD ﬁbroblasts or normal lung ﬁbroblasts
stimulated with TGF-β [16]. HGF consistently inhibited
collagen type I and CTGF accumulation in lung ﬁbroblasts
derived from white subjects. However, HGF had no eﬀect
on collagen or CTGF expression in lung ﬁbroblasts from
black patients, previously shown by us to be the result of
a deﬁciency of HGF-receptor (c-Met) phosphorylation
[16, 18].
In the present study, we compared the activation of
PPARγ in lung ﬁbroblasts isolated from white and black
SSc-ILD patients. As expected, the PPARγ agonist failed to
induce c-Met receptor phosphorylation in lung ﬁbroblasts
from black SSc-ILD patients and controls. Additionally, we
observed that the PPARγ agonist rosiglitazone activated
MMP-1 and reduced collagen type I in SSc-ILD ﬁbroblasts
derived from white subjects; however, it had no eﬀect on
MMP-1andcollagentypeIinSSc-ILDﬁbroblastsfromblack
patients. Furthermore, conditional ablation of the c-Met
receptor by neutralizing antibody abolished the inhibitory
eﬀect of rosiglitazone on MMP-1 and collagen type I, while
overexpression of c-Met receptor restored the eﬀects of
rosiglitazone on collagen I and MMP-1 in lung ﬁbroblasts
isolated from black SSc-ILD patients. In contrast, α-SMA,
CTGF, and NF-κB were reduced by rosiglitazone treatment
to a similar extent in SSc-ILD ﬁbroblasts derived from either
black or white subjects, suggesting that the PPARγ agonist
reduces α-SMA, CTGF, and NF-κB by a mechanism(s)
independent of HGF.
5. Conclusions
We conclude that PPARγ agonists modulate important
ﬁbrogenic events in lung ﬁbroblasts and could be considered
as a potential therapeutic approach to treating patients with
SSc-ILD. We also provide additional foundation for the
biologic diﬀerence between lung ﬁbroblasts from white and
black patients, which might explain the observed diﬀerences
among these racial groups in terms of severity and mortality
from SSc-ILD. Finally, based on these results, diﬀerential
eﬀects of PPARγ agonist therapy might be expected in
patients due in part to diﬀerences in expression of functional
c-Met receptor.
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